Update Breast Cancer 2023, Part 1, Early stage breast cancer = Update Mammakarzinom 2023, Teil 1, Brustkrebs in frühen Krankheitsstadien
Breast cancer - early stage - adjuvant therapy - neoadjuvant therapy - endocrine therapy - biomarkers
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2023
|
| In: |
Geburtshilfe und Frauenheilkunde
Year: 2023, Volume: 83, Issue: 6, Pages: 653-663 |
| ISSN: | 1438-8804 |
| DOI: | 10.1055/a-2074-0551 |
| Online Access: | Resolving-System, kostenfrei: https://doi.org/10.1055/a-2074-0551 Resolving-System, kostenfrei: https://doi.org/10.25673/109849 
|
| Author Notes: | authors: Andreas D. Hartkopf, Christoph Thomssen, Andreas Schneeweiss [und viele weitere] |
| Summary: | Breast cancer - early stage - adjuvant therapy - neoadjuvant therapy - endocrine therapy - biomarkers With abemaciclib (monarchE study) and olaparib (OlympiA study) gaining approval in the adjuvant treatment setting, a significant change in the standard of care for patients with early stage breast cancer has been established for some time now. Accordingly, some diverse developments are slowly being transferred from the metastatic to the adjuvant treatment setting. Recently, there have also been positive reports of the NATALEE study. Other clinical studies are currently investigating substances that are already established in the metastatic setting. These include, for example, the DESTINY Breast05 study with trastuzumab deruxtecan and the SASCIA study with sacituzumab govitecan. In this review paper, we summarize and place in context the latest developments over the past months. |
|---|---|
| Physical Description: | Online Resource |
| ISSN: | 1438-8804 |
| DOI: | 10.1055/a-2074-0551 |